<DOC>
	<DOCNO>NCT02283749</DOCNO>
	<brief_summary>In study patient 's receive medicine Xofigo radioactive drug FDA approve treat prostate cancer spread bone . Xofigo previously test treat lung cancer spread bone . Your doctor study effect , good bad , Xofigo use treat lung cancer spread bone .</brief_summary>
	<brief_title>BrUOG L301 With Non-Small Cell Lung Cancer Bone Metastases</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Radium Ra 223 dichloride</mesh_term>
	<criteria>Age ≥ 18 year . Advanced nonsmall cell lung cancer bone metastasis . Stable respond disease completion initial systemic chemotherapy define RECIST criterion . Site submit confirmation BrUOG . At least 3 week must elapse since completion last chemotherapy 4 week since last radiation , prior first dose Xofigo . Patients permit receive form 'maintenance ' chemotherapy biologic/targeted anticancer therapy treat study Life expectancy least 12 week ( 3 month ) . Patients treat brain metastasis allow , must brain image show evidence stability since recent treatment brain mets , prior first dose Xofigo . For patient brain metastasis , brain imaging require . Patients brain metastasis symptoms potential brain metastasis require baseline brain imaging , must confirm write Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 . Required entry laboratory parameter within 14 day study entry : White Blood Cell Count ( WBC ) ≥ 3,000/mm3 ; Absolute Neutrophil Count ( ANC ) ≥ 1,500/mm3 ; Platelet ( PLT ) count ≥ 100,000/mm3 ; Hemoglobin ( Hgb ) &gt; 9g/dl , Total bilirubin level ≤ 1.5 x institutional upper limit normal ( ULN ) ; Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 2.5 x ULN ; Creatinine ≤ 1.5 x ULN ; Albumin &gt; 2.5 g/dL . Concurrent treatment bisphosphonates denosumab allow . Information start stop date drug dose send BrUOG patient treat concurrently . Prior skeletal related event ( pathologic fracture , radiation surgery bone , spinal cord compression ) allow manage patient stable 4 week prior study entry . Must submit event manage BrUOG documentation confirm eligibility criterion . ( For example , patient experience SSE radiation 2 week must stable 4 week completion radiation prior study entry ) Subjects must able understand willing sign write informed consent form . All acute toxic effect related prior treatment ( ) must resolve NCICTCAE v4 Grade 1 less time signing Informed Consent Form ( ICF ) except alopecia . Women childbearing potential must negative serum pregnancy test perform within 7 day prior start study drug . Postmenopausal woman ( defined menses least 1 year ) surgically sterilize woman require undergo pregnancy test . Subjects ( men woman ) childbearing potential must agree use adequate contraception begin sign ICF least 30 day last dose study drug . The definition adequate contraception base judgment treat physician . Willing able comply protocol , include followup visit examination Received systemic therapy radionuclides ( e.g. , strontium89 , samarium153 , rhenium186 , rhenium188 , Radium Ra 223 dichloride ) treatment bony metastases No prior invasive malignancy within prior two year . However , patient early stage malignancy expect require treatment next 2 year ( early stage , resect breast cancer asymptomatic prostate cancer ) eligible Untreated brain metastasis . Any serious illness medical condition investigator 's opinion would interfere protocol treatment , limited : Any active infection ≥ National Cancer Institute Common Terminology Criteria Adverse Events ( NCICTCAE ) version 4 Grade 2 : Cardiac failure New York Heart Association ( NYHA ) III IV Women pregnant breastfeeding . Inability comply protocol and/or willing available followup assessment . Any condition , investigator 's opinion , make subject unsuitable trial participation . Concurrent anticancer therapy ( chemotherapy , radiation therapy , surgery , immunotherapy , biologic therapy , tumor embolization ) Ra 223 dichloride . Major surgery within 28 day start study drug . Central venous catheter placement consider major surgery .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>NCSLC</keyword>
	<keyword>lung cancer</keyword>
	<keyword>non small cell lung cancer</keyword>
	<keyword>bone metastasis</keyword>
	<keyword>maintenance</keyword>
</DOC>